JAK1 and metabolic syndrome: The observed reduction in the expression of JAK1 supports the potential of CR to attenuate local inflammation in low grade inflammatory diseases (i.e., metabolic syndrome, obesity, and type 2 diabetes) that could predispose to cancer [32,33].